The Pathology Core enables City of Hope Cancer Center investigators to directly study the DNA, RNA and protein in human tumors to validate specific hypotheses generated from pre-clinical studies. It also provides analyses of specific protein expression in tumor tissues to enable scientists to discern the distribution patterns of these proteins in specific cell types. The Pathology Core provides services primarily in the areas of expertise of the members of the Department of Anatomic Pathology. They fall into the following areas: (1) performance and assistance in the routine histological processing of tissues, including paraffin embedding, sectioning, and hematoxylin and eosin (H&E) staining of human tissue, animal tissue, and preparations from cell lines, as well as specialized histological services such as preparation of multi-tumor blocks or tissue arrays to the specifications o1 the researchers;(2) performance and interpretation of immunohistochemistry for the detection of cell products in normal and disease states, including evaluation and technical development of new antibodies as well as the technology to detect multiple antigens in the same histological section;(3) performance and assistance in Laser Capture Microdissection from paraffin or frozen sections to obtain enrichment of specific cell types, including isolation of malignant cells, for the analysis of proteins, RNA and/or DNA content;(4) performance and assistance in preparing formalin-fixed tissues for conventional PCR including RT-PCR;and (5) consultation services to Cancer Center investigators. Expertise in the pathological basis of disease, the histological manifestations of disease, and the use of human tissues for studying disease states is available for the preparation of grants and papers and in the design of experiments. During the prior 12 month reporting period, the Pathology Core provided service to 33 Cancer Center members from all five Research Programs and one non-aligned member. Peer-reviewed usage accounted for 69% of usage during this same reporting period. The proposed annual budget for the core is $406,308, with 28% from the institution, 32% from user fees, and 40% ($160,982) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-28
Application #
8208796
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
28
Fiscal Year
2011
Total Cost
$204,795
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Wu, Chenkai; Ashing, Kimlin Tam; Jones, Veronica C et al. (2018) The association of neighborhood context with health outcomes among ethnic minority breast cancer survivors. J Behav Med 41:52-61
Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37
Wildes, Tanya M; Maggiore, Ronald J; Tew, William P et al. (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26:3563-3570
Paz, Helicia; Joo, Eun Ji; Chou, Chih-Hsing et al. (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17:235-245
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141

Showing the most recent 10 out of 1396 publications